Jump to Main Contents

Home > Division of Cancer RNA Research

Division of Cancer RNA Research

News

Oct. 27, 2025
Wang Xueyan and Wulipan Fulati have joined our lab as postgraduate international research students!
Oct. 22, 2025
Akihide Yoshimi’s project, “Social Implementation of Novel Target Cancer mRNA Vaccine,” has been selected for the Seed Acceleration Program (NCC SAP).
Oct. 20, 2025
Miyu Azuma and Nanami Yamano, who joined us for their training, have published a review article in the Japanese Journal of Clinical Hematology!
Oct. 16, 2025
Masahiko Ajiro gave an invited lecture at the 63rd Annual Meeting of the Japanese Society of Cancer Therapy!
Oct. 16, 2025
Ryoichi Maezono @r_maenosono received the Young Oncologist Award at the 63rd Annual Meeting of the Japanese Society of Cancer Therapy!
Oct. 14, 2025
Akihide Yoshimi was invited to speak at the MM Tour: Tokyo.
Oct. 11, 2025
Akihide Yoshimi delivered an educational lecture at the 87th Annual Meeting of the Japanese Society of Hematology.
Oct. 11, 2025
Tomoya Muto gave an oral presentation at the 87th Annual Meeting of the Japanese Society of Hematology!
Oct. 6, 2025
Our lab website has reached over 50,000 page views! Thank you all for your interest and support!
Oct. 5, 2025
Akihide Yoshimi received the Growth Vision Award at the JST FOREST Panel meeting!
more

Our Research Interest


Our studies have been focused on how RNA processing including RNA splicing is altered in cancer and functionally drives cancer initiation and maintenance. The advent of high-throughput transcriptome sequencing has provided a wealth of information on RNA splicing on a genome-wide scale. It is now understood that > 95% of human genes are subject to alternative splicing. RNA splicing is considered to be a major mediator of proteome diversity through its ability to generate multiple transcripts with differing amino acid sequences from a single gene. The discovery of recurrent mutations in components of the RNA-splicing machinery in 2011 further highlighted the importance of aberrant splicing in cancer as well as a potential therapeutic vulnerability for cells bearing these mutations. Despite the major advances in our understanding of the genomics, molecular biology and therapeutic implications of altered RNA processing in cancer, the full contribution of aberrant RNA splicing to cancer pathogenesis has not been fully elucidated. Our aim is to contribute to the full understanding of the pathogenic roles of altered RNA processing in a variety of cancers and to the development of therapeutically efficacious and safe strategies to improve the outcome of cancer patients.
wordle2.png
(Figure was made by using Wordle based on our recent papers)